Accueil » Communiqués de presse » Valbiotis will present significant preclinical results for its active substance TOTUM•448 against fatty liver diseases (NAFL and NASH), at the annual meeting of the American Association for the Study of Liver Diseases (AASLD).
Les communiqués de presse
27Oct2022
Valbiotis will present significant preclinical results for its active substance TOTUM•448 against fatty liver diseases (NAFL and NASH), at the annual meeting of the American Association for the Study of Liver Diseases (AASLD).
